STOCK TITAN

Armistice Capital and Steven Boyd File Schedule 13G/A for BCYC 4.99% Stake

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 359,703 American Depositary Shares of Bicycle Therapeutics plc, representing 4.99% of the class. Armistice Capital is the investment manager of the Master Fund, the direct holder of the shares, and under an Investment Management Agreement Armistice Capital exercises voting and investment power over those securities. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control.

Positive

  • Clear disclosure of beneficial ownership with exact share count (359,703) and percentage (4.99%)
  • Certification of ordinary-course investment intent stating shares are not held to change control
  • Joint filing coordination clarifies responsibility and relationship among Reporting Persons

Negative

  • None.

Insights

TL;DR A passive sub-5% disclosure showing an investment manager and its managing member with shared voting power over 4.99% of BCYC ADSs.

This Schedule 13G/A reports that Armistice Capital, as investment manager to the Master Fund, and Steven Boyd as its managing member, share voting and dispositive power over 359,703 ADSs representing 4.99% of Bicycle Therapeutics plc's ADS class. The filing emphasizes ordinary-course investment intent and expressly disclaims an intent to influence control of the issuer. For investors, this is a routine beneficial-ownership disclosure reflecting a modest stake by an activist-capable manager but filed under passive ownership rules.

TL;DR Formal joint Schedule 13G/A clarifies roles and confirms shared control signals without alleging change-of-control intent.

The joint filing clarifies that the Master Fund holds the ADSs while Armistice Capital exercises voting and investment power under an Investment Management Agreement and that Mr. Boyd may be deemed to beneficially own the holdings by virtue of his management role. The certification states the shares are held in the ordinary course and not for control purposes. The joint filing statement documents allocation of filing responsibility among the Reporting Persons.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

How many Bicycle Therapeutics plc ADSs does Armistice Capital report owning?

The filing reports 359,703 ADSs, representing 4.99% of the class.

Does the Schedule 13G/A state Armistice Capital intends to influence control of BCYC?

No. The filing includes a certification that the securities are held in the ordinary course of business and not to change or influence control.

Who is the direct holder of the reported shares?

The direct holder is the Armistice Capital Master Fund Ltd., for which Armistice Capital is the investment manager.

What voting and dispositive powers are reported by the filing?

The Reporting Persons report 0 sole voting/dispositive power and 359,703 shared voting and dispositive power.

When was this Schedule 13G/A signed and by whom?

The signatures show Steven Boyd signed on behalf of Armistice Capital and personally, dated 08/14/2025.
Bicycle Therapeutics Limited

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Latest SEC Filings

BCYC Stock Data

484.88M
49.14M
1.4%
88.35%
2.29%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
CAMBRIDGE